ReviewImmunology2015
Inflammation-associated genes: risks and benefits to Foxp3+ regulatory T-cell function.
Review in Immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 11 citations in OpenAlex.
- A Hypothesis-Generating Pharmacologic Profile for Sargramostim Treatment of Parkinson's Disease.Cellular and molecular neurobiology · 2026Trial
- PredictingEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Identifying Therapeutic Targets and Potential Drugs for Diabetic Retinopathy: Focus on Oxidative Stress and Immune Infiltration.Journal of inflammation research · 2025Article
- FOXP3 and GATA3 Polymorphisms, Vitamin D3 and Multiple Sclerosis.Brain sciences · 2021Article
- Pak2 is essential for the function of Foxp3+ regulatory T cells through maintaining a suppressive Treg phenotype.Scientific reports · 2017Article
- Impact of Τh1 and Τh2 cytokines in the progression of idiopathic nephrotic syndrome due to focal segmental glomerulosclerosis and minimal change disease.Journal of nephropathology · 2017Article
- Effect of aging on sputum inflammation and asthma control.The Journal of allergy and clinical immunology · 2017Article
- The Effect of TGF-β on Treg Cells in Adverse Pregnancy Outcome uponFrontiers in microbiology · 2017Article
- Are genetic tests informative in predicting food allergy?Current opinion in allergy and clinical immunology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Foxp3(+) regulatory T (Treg) cells prevent the development of autoimmunity and immunopathology, as well as maintaining homeostasis and tolerance to commensal microorganisms. The suppressive activity of Treg cells is their defining characteristic, generating great interest in their therapeutic potential. However, suppressive and effector functions are not entirely exclusive. Considerable evidence points to the ability of supposedly anti-inflammatory Foxp3-expressing Treg cells to also express transcription factors that have been characterized as cardinal drivers of T effector cell function. We will consider the mounting evidence that Treg cells can function in non-suppressive capacities and review the impetus for this functional change, its relevance to developing immune and autoimmune responses and its significance to the development of Treg-based therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.